Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Melanoma-associated antigen A3 (MAGE-A3)
- Target
- MAGE-A3
- Molecular classification
- Cancer/testis antigens (CT antigens), MAGE-A subfamily
01
Overview
Melanoma-associated antigen A3 (MAGE-A3) is a tumor-specific protein encoded by the MAGEA3 gene. It is a cancer/testis antigen with restricted expression in normal tissues (testes and placenta) but is frequently overexpressed in various malignancies. MAGE-A3 acts as a cellular master regulator by interacting with E3 ubiquitin ligase TRIM28/KAP1, influencing cellular targets such as p53 and AMPK. It is considered an attractive target for immunotherapy due to its tumor specificity and is also a prognostic marker associated with poorer outcomes in several cancers.
- Other names
- CT1.3HIP8HYPDMAGE3MAGEA6MAGE family member A3[3]
02
Mechanism of action
Immunotherapy (vaccine-based therapies)
03
Biological functions
Regulation of tumor suppressor p53Regulation of AMP-activated protein kinase (AMPK)Promotion of proliferationPromotion of metastasisPromotion of survival of tumor cellsMaster regulator via TRIM28/Epigenetic modulation
04
Disease associations
Cancer
05
Safety considerations
Lack of significant benefit in large phase III clinical trialsPotential for off-target effects due to sequence similarity with other MAGE family members
06
Biomarkers
MAGE-A3 mRNA/protein expression levelsAggressive disease phenotypes
Beyond the preview
Go deeper on Melanoma-associated antigen A3 (MAGE-A3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Melanoma-associated antigen A3 (MAGE-A3).